- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Insights on Allogeneic Hematopoietic Cell Transplantation: Values of Older Adult Patients
Sikander Ailawadhi, MD, discusses how the 2024 ASH Annual Meeting’'s study on “"Hematologists’' Approach to Discussing Older Patients’ Values in the Context of Allogeneic Hematopoietic Cell Transplantation”" explored the methodologies hematologists use to engage older patients in treatment decisions, highlighting key findings related to patient values and the importance of incorporating these factors into transplant decision-making for improved patient-centered care.
EP: 1.Unmet Needs and Emerging Trends in Hematologic Cancer Management Around ASH 2024
EP: 2.Insights on CLL and SLL Treatment with BTK Inhibitors: Patient Preferences and Shared Decision-Making
EP: 3.Insights on Multiple Myeloma Treatment: Real-World Data on Survivorship Burden and Patient Preferences
EP: 4.Insights on Allogeneic Hematopoietic Cell Transplantation: Values of Older Adult Patients
EP: 5.Advancing Hematologic Care and the Future of Shared Decision-Making
Video content above is prompted by the following:
- Discuss the data that was were presented at the 2024 ASH Annual Meeting titled in “Hematologists’ Approach to Discussing Older Patients’ Values in the Context of Allogeneic Hematopoietic Cell Transplantation.”
- What was the objective of the study?
- How was this study designed/what methodology was used?
- What results were presented?
Drug Interactions With Ibrutinib Common, Linked to Higher Infection Risk in CLL
September 16th 2025Drug interactions with ibrutinib may not shorten survival when managed carefully, though the significant increase in infection-related hospitalizations tied to CYP3A inhibitors signals an urgent need for closer monitoring, dose adjustment, and proactive infection prevention strategies.
Read More
Real-World Data Support Safety, Efficacy of Venetoclax for CLL
August 29th 2025A single-center study comparing patients with chronic lymphocytic leukemia receiving venetoclax as part of a clinical trial and patients receiving it in routine clinical practice showed very high complete response rates in both groups.
Read More
